Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 808391, 8 pages
Research Article

Healthcare Utilization and Costs of Systemic Lupus Erythematosus in Medicaid

1U.S. Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
2Pharma, Truven Health Analytics Inc., Cambridge, MA 02140, USA
3Pharma, Truven Health Analytics Inc., Washington, DC 20008, USA
4European Market Access at Critical Disease Business Unit, GlaxoSmithKline, London TW8 9GS, UK
5Global Medical Affairs, GlaxoSmithKline, Philadelphia, PA 19102, USA

Received 26 June 2012; Revised 27 October 2012; Accepted 5 November 2012

Academic Editor: Veena K. Ranganath

Copyright © 2013 Hong J. Kan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. Healthcare utilization and costs associated with systemic lupus erythematosus (SLE) in a US Medicaid population were examined. Methods. Patients ≥ 18 years old with SLE diagnosis (ICD-9-CM 710.0x) were extracted from a large Medicaid database 2002–2009. Index date was date of the first SLE diagnosis. Patients with and without SLE were matched. All patients had a variable length of followup with a minimum of 12 months. Annualized healthcare utilization and costs associated with SLE and costs of SLE flares were assessed during the followup period. Multivariate regressions were conducted to estimate incremental healthcare utilization and costs associated with SLE. Results. A total of 14,777 SLE patients met the study criteria, and 14,262 were matched to non-SLE patients. SLE patients had significantly higher healthcare utilization per year than their matched controls. The estimated incremental annual cost associated with SLE was $10,984, with the highest increase in inpatient costs ( ). Cost per flare was $11,716 for severe flares, $562 for moderate flares, and $129 for mild flares. Annual total costs for patients with severe flares were $49,754. Conclusions. SLE patients had significantly higher healthcare resource utilization and costs than non-SLE patients. Patients with severe flares had the highest costs.